ArticleJournal of neuro-oncology2025
Effects of temozolomide dosing on outcome in glioblastoma.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTemozolomide (TMZ) with concomitant radiation is the standard therapy for treating glioblastomas (GBM) and is dosed based on body surface area (BSA) using a goal dose of 75 mg/m
methodsWe conducted a single-center retrospective review of 380 patients with GBM from 2013 to 2024. Relevant data was extracted from electronic medical records. Kaplan-Meier curves and Cox regression models were used to determine survival outcomes.
resultsNo significant impact on survival outcomes was observed when distance from the calculated temozolomide dose was analyzed as a continuous variable (p = 0.156), adjusting for MGMT, the extent of resection, radiation fractions, and Karnofsky performance scores (KPS). Even limited to just MGMT-methylated tumors, TMZ dose did not affect survival. BMI had no impact on survival outcomes. Our subgroup analysis revealed that patients with MGMT-methylated tumors, total resection, higher KPS, and ≥ 30 radiation fractions had improved survival (p < 0.01). Dose interruptions were not more likely with doses above 75 mg/m
conclusionRounding temozolomide doses does not significantly impact survival outcomes or risk of treatment interruptions for patients with GBM. These findings may allow neuro-oncologists to prioritize reducing pill burden and treatment costs without compromising patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.